<?xml version="1.0" encoding="UTF-8"?>

<!--L
  Copyright Oracle Inc

  Distributed under the OSI-approved BSD 3-Clause License.
  See http://ncip.github.com/cadsr-cgmdr-nci-uk/LICENSE.txt for details.
L-->

<cgMDR:Enumerated_Conceptual_Domain xmlns:cgMDR="http://www.cancergrid.org/schema/cgMDR" item_registration_authority_identifier="GB-CANCERGRID-CA" data_identifier="A5EE04418" version="0.1">
    <cgMDR:administered_item_administration_record>
        <cgMDR:administrative_note/>
        <cgMDR:administrative_status>scheduledForReview</cgMDR:administrative_status>
        <cgMDR:creation_date>2008-02-05</cgMDR:creation_date>
        <cgMDR:effective_date>2008-02-05</cgMDR:effective_date>
        <cgMDR:last_change_date>2008-02-05</cgMDR:last_change_date>
        <cgMDR:registration_status>Recorded</cgMDR:registration_status>
    </cgMDR:administered_item_administration_record>
    <cgMDR:administered_by>GB-CANCERGRID-000007-1</cgMDR:administered_by>
    <cgMDR:registered_by>GB-CANCERGRID-000009-1</cgMDR:registered_by>
    <cgMDR:submitted_by>GB-CANCERGRID-000007-1</cgMDR:submitted_by>
    <cgMDR:having>
        <cgMDR:context_identifier>GB-CANCERGRID-000001-1</cgMDR:context_identifier>
        <cgMDR:containing>
            <cgMDR:language_section_language_identifier>
                <cgMDR:country_identifier>GB</cgMDR:country_identifier>
                <cgMDR:language_identifier>eng</cgMDR:language_identifier>
            </cgMDR:language_section_language_identifier>
            <cgMDR:name>Tumour Response End Treatment Lesion 2</cgMDR:name>
            <cgMDR:definition_text>Classification of response to treatment at the end of the treatment cycles for the 2nd breast lesion</cgMDR:definition_text>
            <cgMDR:preferred_designation>true</cgMDR:preferred_designation>
            <cgMDR:definition_source_reference/>
        </cgMDR:containing>
    </cgMDR:having>
    <cgMDR:Value_Meaning>
        <cgMDR:value_meaning_begin_date >2008-02-05</cgMDR:value_meaning_begin_date>
        <cgMDR:value_meaning_description >Complete response</cgMDR:value_meaning_description>
        <cgMDR:value_meaning_identifier >E4C22B965</cgMDR:value_meaning_identifier>
    </cgMDR:Value_Meaning>
    <cgMDR:Value_Meaning>
        <cgMDR:value_meaning_begin_date >2008-02-05</cgMDR:value_meaning_begin_date>
        <cgMDR:value_meaning_description >Partial response</cgMDR:value_meaning_description>
        <cgMDR:value_meaning_identifier >235B6B123</cgMDR:value_meaning_identifier>
    </cgMDR:Value_Meaning>
    <cgMDR:Value_Meaning>
        <cgMDR:value_meaning_begin_date >2008-02-05</cgMDR:value_meaning_begin_date>
        <cgMDR:value_meaning_description >Stable desease</cgMDR:value_meaning_description>
        <cgMDR:value_meaning_identifier >5499ABD46</cgMDR:value_meaning_identifier>
    </cgMDR:Value_Meaning>
    <cgMDR:Value_Meaning>
        <cgMDR:value_meaning_begin_date >2008-02-05</cgMDR:value_meaning_begin_date>
        <cgMDR:value_meaning_description >Progressive desease</cgMDR:value_meaning_description>
        <cgMDR:value_meaning_identifier >459B9E4CD</cgMDR:value_meaning_identifier>
    </cgMDR:Value_Meaning>
    <cgMDR:Value_Meaning>
        <cgMDR:value_meaning_begin_date >2008-02-05</cgMDR:value_meaning_begin_date>
        <cgMDR:value_meaning_description >Non-evaluable</cgMDR:value_meaning_description>
        <cgMDR:value_meaning_identifier >7ADC0EE5E</cgMDR:value_meaning_identifier>
    </cgMDR:Value_Meaning>
</cgMDR:Enumerated_Conceptual_Domain>